Orthocell Ltd · ASX:OCC
Orthocell — Corporate Update (February 2026)
21 slides from Orthocell's corporate update, Feb 2, 2026
Slide 1: US market and operational update
US market and operational update 2 February 2026
Slide 2: Disclaimer
Disclaimer This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, representations contained in this presentation, and they do not accept any liability or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy whatsoever (including in negligence
Slide 3: Commercialisation of Remplir is on-track
Commercialisation of Remplir is on-track TM Australian medical technology company with growing international revenue and US market launch of its flagship nerve repair product, Remplir Fully funded and US Remplir strategy US market share1 to investing in growth is on-track reach cash breakeven2 is le
Slide 4: Company update
Company update
Slide 5: Orthocell three-year vision
Orthocell three-year vision Be at the forefront of regenerative medicine innovation, advancing toward ASX 300 inclusion Business through disciplined growth and a sustainable, well-funded product pipeline goal Build global footprint Win in the Continue growth Advance the Strategic with collagen medic
Slide 6: Focus in FY26
Focus in FY26 Gaining market Strategic Asia Complete UK and EU Recruit specialist access and growing expansion focused on launch planning talent to deepen the customer base high-return Remplir post-Q2 submission expertise and enable of RemplirTM in the US markets for FY27 entry scalable growth Clari
Slide 7: Continued revenue growth
Continued revenue1 growth We have maintained constant growth over the last three halves, driven by device sales Total Revenue by Half (A$M) CHGR +21% 6.2 5.0 4.2 3.5 2H FY24 1H FY25 2H FY25 1H FY26 Orthocell | US Market and Operational Update | February 2026 7 1. Revenue comprises sales revenue, int
Slide 8: US update
US update Gaining market access and growing the customer base of RemplirTM
Slide 9: US peripheral nerve repair trends
US peripheral nerve repair trends Suturing is still the most performed procedure and considered to be the “gold standard” technique for peripheral nerve repair Remplir is not seeking to replace a current dominant market incumbent. Devices are only used in ~10% of procedures Current devices Current d
Slide 10: Significant US market opportunity
Significant US market opportunity Over 700,0001 peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method It is estimated that less than 1% of the market Estimated US market contribution required for cash is required to reach cash breakeven2 breakeven2 compared t
Slide 11: Market access funnel | US Remplir
Market access funnel | US Remplir TM Requirements post FDA approval1 1. Regulatory & Licensing State licensing to allow clinical use of the product Establish sales and support infrastructure including 2. Commercial Channel distributor network Surgeon engagement through product training to gain clini
Slide 12: Market access funnel | US Remplir
Market access funnel | US Remplir TM Requirements post FDA approval1 Progress measures2 1. Regulatory & Licensing State licensing to allow clinical use of the product Approved to sell in 453 states Activities up until 7 direct team members hired 31st Jan Establish sales and support infrastructure in
Slide 13: Combined AAHS, ASPN & ASRM conference
Combined AAHS, ASPN & ASRM conference Chula Vista, California - January 2026
Slide 14: Investing in growth
Investing in growth Deployment of capital raising funds growing capability in the US and manufacturing capacity
Slide 15: Dedicated US team to support scaled growth
Dedicated US team to support scaled growth People Speed to market enabled by team with prior execution experience Sales Medical Education Clinical Affairs Marketing • VP Sales • VP Medical Education • Senior Manager, Clinical • VP Marketing & Medical Affairs • Regional Sales Director East • Medical
Slide 16: Manufacturing expansion – stage 1
Manufacturing expansion – stage 1 Manufacturing Planned capacity upgrades are in place to deliver the volumes estimated and reduce the cost of sale Stage 1 expansion Secure and reliable supply capital approved chain • $5–5.5M investment to expand the • Manufacturing upgrades will office footprint, i
Slide 17: Achievements and upcoming catalysts
Achievements Nerve repair, made SMRT and upcoming catalysts1 US first surgical use Achieved US first sales Achieved Appoint further US sales team members Achieved Appoint first and second distributors in CAN Achieved Appoint first distributor in HKG Achieved EU+UK submissions lodged Achieved Marine
Slide 18: Investment highlights
Investment highlights Commercial stage Product margins Strengthened board Best-in-class platform With ~$50M3 total cash medical technology retained in-house. with highly for Bone, Nerve and reserves and a company progressing Manufacturing facility experienced directors Tendon repair strengthened sha
Slide 19: Questions
Questions N ortho:cell @)
Slide 20: Thank you for attending
yz ortho“ I Thank you for attending
Slide 21: Authorised for release by the Board of Directors of Orthocell Limited
Authorised for release by The Board of Directors of Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com.au orthocell.com